Skip to content

effect of Quetiapine on delirium in patients undergoing coronary artery bypass graft surgery

Investigating the effect of Quetiapine on delirium in patients undergoing coronary artery bypass graft surgery; a double-blind clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130525013456N7
Enrollment
82
Registered
2023-08-21
Start date
2023-08-23
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Determining the effect of Quetiapine on delirium in patients undergoing CABG surgery. Postoperative delirium

Interventions

Intervention 1: Intervention group: The group will receive 12.5 mg of oral quetiapine, the first dose on the morning of surgery, then every 12 hours until 48 hours after surgery (25 mg quetiapine ta

Sponsors

Rasht University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 85 Years

Inclusion criteria

Inclusion criteria: Elective patients who are candidates for coronary artery bypass surgery 85- 35 years American Society of Anesthesiologists (ASA) II,III GCS 15 to be fully alert and able to communicate

Exclusion criteria

Exclusion criteria: Liver and kidney failure Emergency surgery Confirmation of delirium before ICU admission Patients with a history of mental illness and cognitive behavioral problems before surgery Allergy to quetiapine and its ingredients

Design outcomes

Primary

MeasureTime frame
Occurrence of delirium during ICU hospitalization. Timepoint: Daily from the day of surgery until the patient is discharged from the ICU (for 3 days). Method of measurement: CAM- ICU (Confusion Assessment Method for the ICU).

Secondary

MeasureTime frame
Side effects of the drug. Timepoint: Daily. Method of measurement: Observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Sedighinejad

Rasht University of Medical Sciences

A_sedighinejad@yahoo.com+98 13 3332 9524

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026